ASweetLife Team, Author at ASweetLife

FDA Needs More Time to Review MannKind’s New Drug Application for Inhaled Insulin

MannKind Corp. announced that it was informed today by the FDA that they will not be able to complete the review of MannKind's new drug application for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.The FDA explained that it has not yet completed its inspection of the insulin manufacturing facilities of N.V. Organon, a third-party supplier to MannKind....

Review of START FITNESS NOW with Kim Lyons

After completing the entire routine, I can say that I think it’s just right for someone like me. Kim’s positively cheery attitude is infectious and definitely made me want to keep going through all the levels.

Eat Some Avocadodo

That's not a typo. I really did write avocadodo. It's what my son, Guy, says every time I ask him if he'd like to eat some avocado. He then continues to sing what he calls a blessing for the avocado. Guy happens to be a very enthusiastic kid, but he's also right. The avocado is so good for us, it deserves a blessing.

Biodel Inc. Submits New Drug Application to FDA for A New Form of Insulin

Biodel, Inc. announced that it has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for clearance to market of VIAject(R) as a treatment for diabetes. VIAjecta(R) is a formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs. It is Biodel's most advanced product candidate and has been tested in more than 884 patients who participated in Phase 1, 2 and 3 clinical trials...

Novo Nordisk Expects FDA Feedback on Liraglutide Within Days

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide is expected within weeks. Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes...

Good Cholesterol Not As Protective in Type 2 Diabetics

According to a report by The American Heart Association, a small European study shows high-density lipoprotein (HDL), known as “good” cholesterol, isn’t as protective for people with type 2 diabetes. HDL carries cholesterol out of the arteries, and high levels are associated with a lower risk of heart disease...

Jay Cutler Releases Fifth “Touchdowns for Diabetes” Episode

Jay Cutler has not let type 1 diabetes hold him back from doing what he loves. Since being diagnosed after his second season in the NFL he has worked to help inspire children with diabetes to achieve their goals, and let them see that diabetes doesn't have to stop them from being who they want to be..

JDRF Announces Diabetes Research Program with Johnson & Johnson

The Juvenile Diabetes Research Foundation announced today in a press release that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes...

Is Lantus Insulin Linked to Increased Risk of Cancer? New Study Begins

Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association...

IDF to launch new initiative to promote translational research and twinning

The International Diabetes Federation (IDF) announced that on January 15 2010, it will launch D-START (Diabetes, Supporting Translational Research and Twinning), an initiative that aims to support the development of innovative projects in low and middle- income countries...